Gilead Shows More Pipeline Progress - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 16 mins ago
Gilead (GILD) announced encouraging results from a study on the combination of Ranexa and Multaq.
Illumina Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 1:10PM CDT
On May 10, we upgraded Illumina Inc. (ILMN) to a Zacks Rank #1 (Strong Buy).
Strength Seen in Medivation (MDVN): Stock Up 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:25AM CDT
Medivation (MDVN) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Q1 Loss Wider than Expected at Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 2:30PM CDT
Following the disappointing earnings performance, Genomic Health's share price declined 1.5% on May 8.
Myriad Genetics to Present at the Bank of America 2014 Healthcare Conference
GlobeNewswire - Fri May 09, 6:18AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference, at 10:00 a.m. Pacific on May 13, 2014, at the Encore at the Wynn in Las Vegas, Nevada.
Myriad Genetics Drops despite Earnings, Revs Beat; Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 2:00PM CDT
Myriad Genetics (MYGN) reported EPS of 60 cents in the third quarter of fiscal 2014.
The Nasdaq's 3 Most Hated Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed May 07, 5:16PM CDT
The Nasdaq Composite may be showing its first vulnerability in more than a year due to weakness in social-networking stocks, but it's still up 20% on a trailing 12-month basis. There is a laundry list of reasons why the Nasdaq has soared. This...
Analysis of Automated Microbiology Instrumentation and Strategic Profiles of Leading Suppliers
M2 - Wed May 07, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c9zbx3/analysis_of) has announced the addition of the "Analysis of Automated Microbiology Instrumentation and Strategic Profiles of Leading Suppliers" report to their offering. This new 148-page report reviews current instrumentation technologies, and profiles features of leading automated and semi-automated Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic analyzers. The report also presents strategic assessments of current and emerging suppliers of microbiology products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon. Key Topics Covered: Introduction 1. Major Factors Affecting Market Penetration of Microbiology Instrumentation 2. Traditional Practices 3. Technological Challenges 4. Automation: Impact on the Microbiology Laboratory and the Patient Major Microbiology Automated and Semiautomated Systems 1. Multiple Purpose Microbiology Systems 2. Specialized Microbiology Systems 3. Molecular Diagnostic Systems 4. Immunodiagnostic Systems Companies Mentioned: - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Biokit - Biotest - Caliper - Cepheid - Decode - DiaSorin - Diadexus - Diamedix - Eiken Chemical - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Hologic/Gen-Probe - ID Biomedical/GSK - Illumina - Kreatech - Li-Cor Biosciences - Life Technology - Lonza - Monogram Biosciences - Myriad Genetics - Nanogen/Elitech - Novartis Diagnostics/Grifols - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - SeraCare - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan - Thermo Fisher - Wako - Wallac/PE - bioMerieux For more information visit http://www.researchandmarkets.com/research/c9...nalysis_of
Myriad Genetics Reports Financial Results for Third Quarter of Fiscal Year 2014
GlobeNewswire - Tue May 06, 3:23PM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for the fiscal third quarter and nine months ended March 31, 2014, increased its fiscal year 2014 guidance, and provided an update on recent business highlights. Revenue for the third quarter was $182.9 million, a 17 percent increase over the same period in the prior year. Third quarter GAAP earnings per diluted share were $0.48, which included a $12.6 million one-time, non-cash expense associated with the purchase of Crescendo Bioscience, Inc. during the quarter and a $1.2 million non-cash amortization of acquired intangible assets. Excluding these non-cash charges, third quarter adjusted earnings per diluted share were $0.60, a 30 percent increase over the same period in the prior year. A reconciliation of GAAP to adjusted earnings per diluted share is provided in the financial section of this earnings release.
Will Allscripts Healthcare Solutions (MDRX) Miss Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 3:10PM CDT
Allscripts's earnings slumped 55.6% year over year to 4 cents per share in the fourth quarter of 2013.
Quiet Session Intensifies As Stocks Hit Session Lows
at Investor's Business Daily - Tue May 06, 2:01PM CDT
Selling picked up the pace Tuesday as stocks fell to session lows with a little over one hour left in the session. The Nasdaq dropped 1.1%; the S&P 500 lost 0.8% and the Dow Jones industrial average gave up 0.7%. NYSE and Nasdaq volume was tracking...
Stocks Extend Losses; AerCap Hits High On Earnings
at Investor's Business Daily - Tue May 06, 10:56AM CDT
Stocks were trading near session lows about two hours into Tuesday's session. The Nasdaq and Dow Jones industrial average each fell 0.5% while the S&P 500 gave up 0.4%. NYSE and Nasdaq volume was tracking 5% higher than Monday's light levels. In the...
Critical Alerts For Chipotle Mexican Grill, Advanced Micro Devices, Myriad Genetics, JinkoSolar, and Rosetta Resources Released By InvestorsObserver
PR Newswire - Tue May 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMG, AMD, MYGN, JKS, and ROSE.
Myriad and UnitedHealthcare Sign Three-Year Agreement Making myRisk(TM) Hereditary Cancer Test Available to United Members
GlobeNewswire - Tue May 06, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed a three-year contract with UnitedHealthcare. The contract provides UnitedHealthcare with access for BRCA testing and the myRisk Hereditary Cancer test for patients who meet the hereditary cancer testing eligibility criteria.
United States Molecular Diagnostics Market, Test Volume Forecast & Companies Report 2014-2018
M2 - Tue May 06, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8kwhmq/united_states) has announced the addition of the "United States (USA)-Molecular Diagnostics Market, Test Volume Forecast & Companies" report to their offering. United States Molecular Diagnostics Market & Future Forecast to 2018 Overview Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being added continuously. Molecular diagnostics is the promising area which can transform disease diagnosis, as diagnosis based on symptoms and use of surrogate markers is replaced by genomic and proteomic analysis. This fundamental shift offers the promise for early disease detection, potentially before symptoms have even occurred. United States molecular diagnostic market for 2018 is anticipated to more than double from its current value in 2013. In United States molecular diagnostic market, infectious disease controls the highest market share in 2013. But in terms of test volume food pathogen testing takes the lead pushing infectious disease at number two position. Molecular oncology tests have emerged as a significant rapidly growing market segment. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. United States constitutes the largest regional market for blood screening and blood products. Molecular diagnostics is also starting to emerge as an important tool for HLA Testing, Food Pathogen Detection Testing and other disease areas. In companies market share Hologic Inc., Myriad Genetics and Becton Dickinson together these 3 companies control more than 50% market share for 2013. However Becton Dickinson is expected to lose its market share gradually and Roche is expected to take its place by 2018. United States Molecular Diagnostics Market & Test Volume - Application Segment Analysis (2010 - 2018) 1. Oncology Testing 2. Infectious Diseases 3. Genetic Testing 4. Blood Screening 5. Food Pathogen Testing 6. Tissue Typing (HLA Testing) United States Molecular Diagnostics - Company Wise Sales Analysis (2010 - 2018) 1. Roche 2. Abbott 3. Myriad Genetics 4. BioMerieux 5. Qiagen 6. Hologic Inc. 7. Becton Dickinson 8. Siemens 9. Cepheid 10. Others Key Topics Covered: 1. Executive Summary 2. United States Molecular Diagnostics Market, Test Volume & Forecast (2010 - 2018) 3. United States Molecular Diagnostics Market & Volume Share (2010 - 2018) 4. United States Molecular Diagnostics Market & Forecast - Application Wise 5. United States Molecular Diagnostics Test Volume - Application Wise 6. United States Molecular Diagnostics Market - Company Wise 7. United States Molecular Diagnostics Market - Driving Factors 8. United States Molecular Diagnostics Market - Challenges For more information visit http://www.researchandmarkets.com/research/8k...ted_states
5 Stocks Set to Soar on Bullish Earnings
at The Street - Mon May 05, 11:05AM CDT
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
Geron Reports In-Line Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 8:50AM CDT
Geron (GERN) is working on gathering data required by the FDA to lift the clinical hold on imetelstat.
Is A Short Squeeze Ahead for Myriad Genetics (MYGN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 05, 7:59AM CDT
Is A Short Squeeze Ahead for Myriad Genetics (MYGN)?
Should You Buy Myriad Genetics (MYGN) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 05, 7:36AM CDT
Myriad Genetics could beat earnings estimates this season backed by favorable earnings estimate revision activity
Ubiquiti, Avis Budget Among 5 IBD 50 Stocks Reporting
at Investor's Business Daily - Sat May 03, 7:02AM CDT
As the market works through correction, new leaders are positioning to shoot out of the gate when they get a green light. Few leaders race to the front of the pack without passing through the IBD 50 list of top-rated stocks. Today's IBD 50 includes a...